10-K: LENZ Therapeutics Launches VIZZ, Reports Initial Sales and Continued Losses

LENZ Therapeutics commercially launched VIZZ, its FDA-approved presbyopia eye drop, in the U.S. in August 2025, generating initial product sales while continuing to incur significant net losses.

Summary

• LENZ Therapeutics is a commercial pharmaceutical company focused on developing and commercializing innovative therapies to improve vision.
• On July 31, 2025, the FDA approved VIZZ (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia.
• VIZZ commercially launched in the U.S. in August 2025, with product sample distribution to eye care professionals (ECPs) and commercial shipments via an e-pharmacy partner initiated in October 2025, and broad retail availability beginning in November 2025.
• VIZZ is a once-daily eye drop designed to restore clear near vision for up to 10 hours, utilizing a pupil-selective miotic mechanism that achieves a sub-2mm pupil without causing a myopic shift.
• The estimated U.S. market opportunity for VIZZ is in excess of $3 billion, targeting an estimated 128 million presbyopes.
• The company reported a net loss of $82.1 million for the year ended December 31, 2025, compared to $49.8 million for the year ended December 31, 2024.
• As of December 31, 2025, the accumulated deficit was $227.1 million.
• Cash, cash equivalents, restricted cash, and marketable securities totaled $292.3 million as of December 31, 2025.
• Initial product sales, net, for the year ended December 31, 2025, were $1.588 million, primarily from approximately 20,000 paid prescriptions.
• License revenue for 2025 was $17.5 million, including $10.0 million from CORXEL Pharmaceuticals milestones and $7.5 million from Lotus Pharmaceutical Co., LTD. and Laboratoires Tha upfront payments.
• Selling, general and administrative expenses increased by 216% to $91.1 million in 2025, driven by commercialization efforts.
• Research and development expenses decreased by 37% to $18.7 million in 2025, primarily due to VIZZ's FDA approval.
• The company believes its existing cash, cash equivalents, and marketable securities as of December 31, 2025, will be sufficient to fund operations to positive operating cash flow.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report, reflecting successful product launch and strong clinical data for VIZZ, but tempered by significant ongoing losses and intense market competition typical for a commercial-stage pharmaceutical company.

Positives

• FDA approval of VIZZ (aceclidine ophthalmic solution) 1.44% on July 31, 2025, marks it as the first and only aceclidine-based eye drop for presbyopia.
• Successful commercial launch of VIZZ in the U.S. in August 2025, with product samples distributed in October and broad retail availability in November.
• VIZZ demonstrated rapid onset (71% achieved three-lines or greater improvement at 30 minutes) and long duration (40% achieved three-lines or greater improvement at 10 hours) in Phase 3 CLARITY 2 trials.
• VIZZ was well-tolerated with no serious treatment-related adverse events observed across over 30,000 treatment days in the CLARITY study.
• Patent protection for VIZZ in the U.S. extends until at least 2044, with five years of New Chemical Entity (NCE) exclusivity expiring in July 2030.
• The estimated U.S. market opportunity for VIZZ exceeds $3 billion, targeting 128 million presbyopes.
• Market research indicated high willingness among presbyopes to use a daily prescription eye drop (95% would consider, 60% seriously consider).
• 75% of CLARITY trial participants wished to continue using VIZZ after the study, with 81% indicating at least four times a week use.
• Secured international licensing and distribution partnerships for Greater China (CORXEL), South Korea and Southeast Asia (Lotus), Canada (Tha), and the Middle East (Lunatus).
• Submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for VIZZ in March 2026.
• Strong cash position of $292.3 million as of December 31, 2025, with the expectation to fund the company to positive operating cash flow.
• Generated initial product sales of $1.588 million and license revenue of $17.5 million in 2025.

Negatives

• Incurred significant net losses ($82.1 million in 2025, $49.8 million in 2024) and negative cash flows from operations since inception, with an accumulated deficit of $227.1 million.
• The business depends entirely on VIZZ, with no additional product candidates currently in the development pipeline.
• VIZZ may fail to achieve sufficient market acceptance by ECPs and patients, or the market opportunity may be smaller than estimated.
• Faces significant competition from existing and developing presbyopia therapies, including branded, generic, and off-label products.
• High costs associated with building and expanding sales, marketing, and distribution infrastructure for commercialization.
• Reliance on third-party manufacturers for VIZZ increases risks of supply disruption or inadequate quantities.
• Potential for adverse side effects from aceclidine, even if minimal, could inhibit commercialization.
• Subject to ongoing regulatory obligations and oversight, which may result in significant additional expense and penalties for non-compliance.
• The market price of common stock is expected to be volatile.
• As an emerging growth company and smaller reporting company, reduced reporting requirements may make its common stock less attractive to some investors.

Risks

• Limited operating history and significant losses/negative cash flows since formation, making future success and viability difficult to predict.
• Business depends entirely on the development and commercialization of VIZZ; failure to successfully commercialize VIZZ would materially harm the business.
• VIZZ may fail to achieve market acceptance by ECPs and patients, and the market opportunity for VIZZ may be smaller than estimated.
• Significant competition from other pharmaceutical companies developing or marketing presbyopia therapies, including existing branded, generic, and off-label products.
• Inability to establish or maintain sufficient sales and marketing capabilities or enter into agreements with third parties on acceptable terms.
• Inability to obtain and maintain sufficient intellectual property protection for VIZZ, or if the scope is not broad enough, allowing competitors to develop and commercialize similar products.
• Reliance on third parties for the manufacture of VIZZ increases the risk of insufficient quantities or unacceptable costs.
• Third-party manufacturers may encounter difficulties in production, delaying or preventing adequate supply of VIZZ.
• Success is highly dependent on the ability to attract and retain highly skilled executive officers and employees.
• The market price of common stock is expected to be volatile.
• Need to raise additional financing in the future, which may not be available on favorable terms or at all, potentially diluting stockholders' ownership interests.
• VIZZ is based on aceclidine, an active pharmaceutical ingredient previously approved and marketed outside the U.S. for glaucoma, exposing the company to risks like generic competition in Europe and potential adverse side effects from incorrect dosages.
• VIZZ or future product candidates may fail to demonstrate substantial evidence of safety and efficacy or cause significant adverse events, which could prevent, delay, or limit regulatory approval and market acceptance.
• Product liability lawsuits could result in substantial liabilities and may require limiting commercialization of VIZZ.
• Risks associated with marketing products internationally, including differing regulatory requirements, economic weakness, political instability, and trade policies.
• Inability to protect intellectual property rights throughout the world, particularly in countries with less extensive protection than the U.S.
• May become involved in third-party claims of intellectual property infringement, which could delay or prevent commercialization.
• Lawsuits to protect or enforce patents or other intellectual property rights could be expensive, time-consuming, and unsuccessful, potentially leading to patents being found invalid or unenforceable.
• Changes in U.S. patent law or the patent law of other countries could diminish the value of patents in general.
• Inability to protect the confidentiality of trade secrets could harm business and competitive position.
• May be subject to claims that employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of former employers or other third parties.
• May not be able to license or acquire new or necessary intellectual property rights or technology from third parties.
• The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming, and inherently unpredictable.
• Despite FDA approval of VIZZ, the company will be subject to ongoing regulatory obligations and continued regulatory oversight, which may result in significant additional expense and penalties for non-compliance.
• Disruptions at the FDA, SEC, and other government agencies caused by funding shortages or global health concerns could hinder their ability to perform normal business functions.
• May face difficulties from changes to current regulations and future legislation, including healthcare legislative measures aimed at reducing healthcare costs.
• Subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, and health information privacy and security laws, which could expose the company to criminal sanctions and civil penalties.
• Internal computer systems, or those of third parties, may fail or suffer actual or suspected security or privacy breaches or incidents.
• The disposal of Graphite's historical assets and operations in connection with the Merger made the company subject to SEC requirements applicable to reporting shell company business combinations, leading to more stringent reporting requirements and offering limitations.
• If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about the company, its stock price and trading volume could decline.
• May be subject to adverse legislative or regulatory tax changes that could negatively impact financial condition.
• Ability to use net operating loss carryforwards and other tax attributes may be limited under Sections 382 and 383 of the Code.
• Unfavorable global economic conditions could adversely affect business, financial condition, results of operations, or cash flows.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses in the early stages of VIZZ commercialization, driven by sales, marketing, manufacturing, and distribution costs, as well as additional costs associated with being a public company. However, existing cash, cash equivalents, and marketable securities as of December 31, 2025, are anticipated to fund the company to positive operating cash flow. The company plans to expand its sales force in Q2 2026 and continue to opportunistically seek international partnerships for VIZZ in Europe, Latin America, and other markets.

Management Comments

• "It is our goal to successfully commercialize VIZZ, and we have assembled an executive team with extensive clinical and commercial experience to execute this goal and become the category leader."
• "We believe that VIZZ will become the leading brand for presbyopes, by improving near vision throughout the full workday."
• "We believe VIZZ has the unique characteristics to become the leading solution for the treatment of presbyopia, will most effectively meet the needs of the widest range of presbyopes and best create loyalty and value based on an 'all eyes, all day' brand mission."
• "We believe that our existing cash, cash equivalents and marketable securities as of December 31, 2025 will allow us to continue to commercialize VIZZ, and will be sufficient to fund the Company to positive operating cash flow."

Industry Context

StockSavvy.ai notes that the presbyopia market is substantial, impacting an estimated 1.8 billion people globally and 128 million in the U.S., and is growing due to the aging general population. This market is consumer-driven and cash-pay, exhibiting dynamics similar to contact lenses and cosmetic procedures like Botox, which suggests a high willingness among consumers to pay out-of-pocket for differentiated solutions. VIZZ enters a competitive landscape with existing FDA-approved pharmaceutical treatments such as AbbVie's Vuity, Orasis's Qlosi (both pilocarpine-based), and Amneal Therapeutics' generic Vuity, with Tenpoint Therapeutics' carbachol-based Yuvezzi expected to launch in Q2 2026.

Comparison to Industry Standards

• VIZZ (aceclidine-based) is differentiated from competitors like Vuity and Qlosi (pilocarpine-based) and Yuvezzi (carbachol-based) by its pupil-selective miotic mechanism, designed to achieve a sub-2mm pupil diameter without causing a significant myopic shift or negatively impacting distance vision.
• In CLARITY 2 trials, VIZZ showed 71% of participants achieved three-lines or greater improvement in near visual acuity at 30 minutes, and 40% maintained this improvement at 10 hours. This contrasts with competitor Vuity, where eye care professionals (ECPs) reported lower-than-expected efficacy and duration, with 66% of patients not seeing duration past four hours, despite a primary endpoint of three hours.
• Vuity's label was amended to include a warning related to retinal tears and detachments, a risk believed to be reduced with aceclidine due to its minimal effect on the ciliary muscle.
• Vuity was primarily tested in younger presbyopes (ages 40-55, average 50), while VIZZ is expected to benefit a wider age range (mid-40s to mid-70s) and broader refractive range due to its mechanism not requiring remaining accommodation.
• Independent studies show aceclidine's independence ratio (22-28) is significantly higher than pilocarpine (1.6-1.9) and carbachol (5.3-5.4), indicating superior pupil-selectivity and less ciliary muscle stimulation.
• 2% aceclidine demonstrated a negligible myopic shift compared to -1.3D for 2% pilocarpine and -1.15D for 3% carbachol, where a 1.0D shift can reduce 20/20 vision to 20/50 distance vision.

Corporate Governance

Legal Proceedings

• Not currently a party to or aware of any proceedings that are believed to have, individually or in the aggregate, a material adverse effect on the business, financial condition, or results of operations.
• The company has been subject to litigation and received demands in connection with the Merger, as previously disclosed in public filings.

Related Party Transactions

• Through the March 2024 PIPE Financing, 3,343,330 shares were issued to investors who had designated members on the company's board of directors.
• A member of the company's board of directors also serves on the board of a vendor providing manufacturing services. Total fees incurred with this related-party vendor were $0.9 million in 2025 and $0.5 million in 2024, charged to research and development expenses (prior to FDA approval) and selling, general and administrative expenses (post-FDA approval).
• The company had $0.1 million due to this vendor within accounts payable at both December 31, 2025, and December 31, 2024.

Stakeholder Impact

• Shareholders: Potential for dilution from future capital raises, volatility in stock price, and impact of reduced reporting requirements as an emerging growth company. Anti-takeover provisions in corporate governance documents could affect acquisition premiums.
• Employees: Company's success is highly dependent on attracting and retaining skilled personnel; equity incentive plans and an employee stock purchase plan are in place to incentivize and retain staff.
• Customers (Patients): VIZZ aims to improve near vision for presbyopes, offering a once-daily, well-tolerated solution. The self-pay model is designed to offer immediate patient access.
• Eye Care Professionals (ECPs): The company's commercial strategy is focused on targeting and partnering with high-prescribing ECPs to drive product adoption and provide an alternative treatment option for presbyopia.
• Suppliers/Manufacturers: Reliance on third-party contract manufacturing organizations (CMOs) and active pharmaceutical ingredient (API) suppliers introduces risks of supply disruptions or production difficulties.
• Regulatory Bodies: The company is subject to extensive and ongoing regulation by the FDA and other international authorities, requiring continuous compliance and potentially significant expenses.

Next Steps

• Continue to expand and manage the sales, marketing, and distribution infrastructure for VIZZ in the U.S.
• Expand the sales organization by an additional 29 territories in Q1 2026, with full deployment expected in Q2 2026.
• Continue to establish licensing and distribution partnerships internationally for VIZZ.
• Opportunistically evaluate strategic and commercial opportunities, including developing, in-licensing, or partnering other products or product candidates.
• Actively seek to obtain broader intellectual property protection for VIZZ, including new methods of use, formulations, and dosing regimens.
• Monitor and test cybersecurity safeguards and train employees on policies.
• Lotus Pharmaceutical Co., LTD. to continue seeking regulatory approvals for VIZZ in South Korea, Thailand, and Singapore.
• Await European Medicines Agency (EMA) review and approval of VIZZ following the Marketing Authorization Application (MAA) submission in March 2026.
• Tenpoint Therapeutics may launch Yuvezzi in Q2 2026, increasing competition in the presbyopia market.

Key Dates

Recommendation

LENZ Therapeutics has achieved a significant milestone with FDA approval and initial commercial launch of VIZZ, demonstrating strong clinical data and establishing international partnerships. The company's substantial cash reserves are a positive for funding operations to positive cash flow. However, it is still in the very early stages of commercialization, facing intense competition, significant ongoing losses, and the inherent risks of market acceptance for a new pharmaceutical product. A 'Hold' recommendation reflects the potential for future growth balanced against the substantial execution risks and current unprofitability.

Keywords

Presbyopia, VIZZ, Aceclidine, Ophthalmic Solution, Eye Drop, FDA Approval, Commercial Launch, Pharmaceutical, Vision Correction, Miotics, Clinical Trials, Intellectual Property, Biotechnology, Healthcare, SEC Filing, 10-K, LENZ Therapeutics